Biomarkers, Bundled Payments, and Colorectal Cancer Care

Genes and Cancer

Volumn 3, Issue 1, 2012, Pages 16-22

  Ross, William ^a   Lynch, Patrick ^a   Raju, Gottumukkala ^a   Rodriguez, Alma ^a   Burke, Thomas ^a   Hafemeister, Lisa ^a   Hawk, Ernest ^a   Wu, Xifeng ^a   DuBois, Raymond N ^a   Mishra, Lopa ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

biomarkers; bundled payments; colorectal cancer; health care reform; health policy

Indexed keywords

APC PROTEIN; B RAF KINASE; BIOLOGICAL MARKER; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; IRINOTECAN; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; OXALIPLATIN;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER STAGING; COLORECTAL CANCER; COST BENEFIT ANALYSIS; COST MINIMIZATION ANALYSIS; COST OF ILLNESS; EVIDENCE BASED PRACTICE; GENE; GENE MUTATION; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH CARE QUALITY; HEALTH CARE UTILIZATION; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; MICROSATELLITE INSTABILITY; MISMATCH REPAIR GENE; OVERALL SURVIVAL; PRIORITY JOURNAL; TREATMENT RESPONSE; TUMOR SUPPRESSOR GENE;

EID: 84868642293     PISSN: 19476019     EISSN: 19476027     Source Type: Journal    
DOI: 10.1177/1947601912448958     Document Type: Article

References (57)

1. Siegel R,Ward E,Brawley O,Jemal A.Cancer statistics: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths.CA Cancer J Clin. 2011;61:212-36.
2. Yabroff KR,Mariotto AB,Feuer E,Brown ML.Projections of the costs associated with colorectal cancer care in the United States, 2000-2020.Health Econ. 2008;17:947-59.
3. Ferro SA,Myer BS,Wolff DA,et al.Variation in the cost of medications for the treatment of colorectal cancer.Am J Manag Care. 2008;14:717-25.
4. Lang K,Lines LM,Lee DW,Korn JR,Earle CC,Menzin J.Lifetime and treatment-phase costs associated with colorectal cancer: evidence from SEER-Medicare data.Clin Gastroenterol Hepatol. 2009;7:198-204.
5. Lancet. 2010 1618;376:.
6. Rex DK,Petrini JL,Baron TH,et al.Quality indicators for colonoscopy.Gastrointest Endosc. 2006;63:S16-28.
7. Chen SC,Rex DK.Endoscopist can be more powerful than age and male gender in predicting adenoma detection at colonoscopy.Am J Gastroenterol. 2007;102:856-61.
8. Dahabreh IJ,Terasawa T,Castaldi PJ,Trikalinos TA.Systematic review: anti-epidermal growth factor receptor treatment effect modification by KRAS mutations in advanced colorectal cancer.Ann Intern Med. 2011;154:37-49.
9. Deschoolmeester V,Baay M,Specenier P,Lardon F,Vermorken JB.A review of the most promising biomarkers in colorectal cancer: one step closer to targeted therapy.Oncologist. 2010;15:699-731.
10. Kelley RK,Van Bebber SL,Phillips KA,Venook AP.Personalized medicine and oncology practice guidelines: a case study of contemporary biomarkers in colorectal cancer.J Natl Compr Canc Netw. 2011;9:13-25.
11. Wood LD,Parsons DW,Jones S,et al.The genomic landscapes of human breast and colorectal cancers.Science. 2007;318:1108-13.
12. Van Cutsem E,Kohne CH,Lang I,et al.Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status.J Clin Oncol. 2011;29:2011-9.
13. Bokemeyer C,Bondarenko I,Hartmann JT,et al.Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study.Ann Oncol. 2011;22:1535-46.
14. Allegra CJ,Jessup JM,Somerfield MR,et al.American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy.J Clin Oncol. 2009;27:2091-6.
15. Van Cutsem E,Nordlinger B,Cervantes A.Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment.Ann Oncol. 2010;21 (Suppl 5): v93-7.
16. Tol J,Dijkstra JR,Klomp M,et al.Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab.Eur J Cancer. 2010;46:1997-2009.
17. Pritchard CC,Grady WM.Colorectal cancer molecular biology moves into clinical practice.Gut. 2011;60:116-29.
18. De Roock W,De Vriendt V,Normanno N,Ciardiello F,Tejpar S.KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer.Lancet Oncol. 2011;12:594-603.
19. Fearon ER,Vogelstein B.A genetic model for colorectal tumorigenesis.Cell. 1990;61:759-67.
20. Vogelstein B,Fearon ER,Hamilton SR,et al.Genetic alterations during colorectal-tumor development.N Engl J Med. 1988;319:525-32.
21. Jones S,Chen WD,Parmigiani G,et al.Comparative lesion sequencing provides insights into tumor evolution.Proc Natl Acad Sci U S A. 2008;105:4283-8.
22. Guda K,Moinova H,He J,et al.Inactivating germ-line and somatic mutations in polypeptide N-acetylgalactosaminyltransferase 12 in human colon cancers.Proc Natl Acad Sci U S A. 2009;106:12921-5.
23. Cummins JM,He Y,Leary RJ,et al.The colorectal microRNAome.Proc Natl Acad Sci U S A. 2006;103:3687-92.
24. Yao ZX,Jogunoori W,Choufani S,et al.Epigenetic silencing of beta-spectrin, a TGF-beta signaling/scaffolding protein in a human cancer stem cell disorder: Beckwith-Wiedemann syndrome.J Biol Chem. 2010;285:36112-20.
25. Feinberg AP.Phenotypic plasticity and the epigenetics of human disease.Nature. 2007;447:433-40.
26. Peltomaki P,Lothe RA,Aaltonen LA,et al.Microsatellite instability is associated with tumors that characterize the hereditary non-polyposis colorectal carcinoma syndrome.Cancer Res. 1993;53:5853-5.
27. Albano WA,Recabaren JA,Lynch HT,et al.Natural history of hereditary cancer of the breast and colon.Cancer. 1982;50:360-3.
28. Aaltonen LA,Peltomaki P,Leach FS,et al.Clues to the pathogenesis of familial colorectal cancer.Science. 1993;260:812-6.
29. Ribic CM,Sargent DJ,Moore MJ,et al.Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer.N Engl J Med. 2003;349:247-57.
30. Sargent DJ,Marsoni S,Monges G,et al.Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer.J Clin Oncol. 2010;28:3219-26.
31. Sinicrope FA,Foster NR,Thibodeau SN,et al.DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy.J Natl Cancer Inst. 2011;103:863-75.
32. Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives.Genet Med. 2009;11:35-41.
33. Ladabaum U,Wang G,Terdiman J,et al.Strategies to identify the Lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis.Ann Intern Med. 2011;155:69-79.
34. Wilson PM,Labonte MJ,Lenz HJ.Molecular markers in the treatment of metastatic colorectal cancer.Cancer J. 2010;16:262-72.
35. Samowitz WS,Sweeney C,Herrick J,et al.Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers.Cancer Res. 2005;65:6063-9.
36. Ogino S,Nosho K,Kirkner GJ,et al.CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer.Gut. 2009;58:90-6.
37. Noffsinger AE.Serrated polyps and colorectal cancer: new pathway to malignancy.Annu Rev Pathol. 2009;4:343-64.
38. O'Connell MJ,Lavery I,Yothers G,et al.Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin.J Clin Oncol. 2010;28:3937-44.
39. Cronin DP,Harlan LC,Potosky AL,Clegg LX,Stevens JL,Mooney MM.Patterns of care for adjuvant therapy in a random population-based sample of patients diagnosed with colorectal cancer.Am J Gastroenterol. 2006;101:2308-18.
40. Miller HD.From volume to value: better ways to pay for health care.Health Aff (Millwood). 2009;28:1418-28.
41. Hussey PS,Sorbero ME,Mehrotra A,Liu H,Damberg CL.Episode-based performance measurement and payment: making it a reality.Health Aff (Millwood). 2009;28:1406-17.
42. Kocher R,Sahni NR.Physicians versus hospitals as leaders of accountable care organizations.N Engl J Med. 2010;363:2579-82.
43. Yabroff KR,Warren JL,Brown ML.Costs of cancer care in the USA: a descriptive review.Nat Clin Pract Oncol. 2007;4:643-56.
44. SmithPWitterS. Risk pooling in health care financing: The implications for health system performance. Health Nutrition and Population Discussion Paper. Washington, DC: The International Bank for Reconstruction and Development, The World Bank; 2004. January22, 2011. Available from: http://siteresources.worldbank.org/HEALTHNUTRITIONANDPOPULATION/Resources/2816271095698140167/Chap95SmithWitterRiskPoolingFinal.pdf.
45. de Brantes F,Rosenthal MB,Painter M.Building a bridge from fragmentation to accountability: the Prometheus payment model.N Engl J Med. 2009;361:1033-6.
46. Rand Corporation. Analysis of bundled payment. Santa Monica, CA: Rand Corporation; 2011. January12, 2011. Available from: www.randcompare.org/analysis-of-options/analysis-of-bundled-payment.
47. Berwick DM,Nolan TW,Whittington J.The triple aim: care, health, and cost.Health Aff (Millwood). 2008;27:759-69.
48. Walston SL,Kimberly JR,Burns LR.Owned vertical integration and health care: promise and performance.Health Care Manage Rev. 1996;21:83-92.
49. Burns LR,Pauly MV.Integrated delivery networks: a detour on the road to integrated health care?.Health Aff (Millwood). 2002;21:128-43.
50. Thaldorf C,Liberman A.Integration of health care organizations: using the power strategies of horizontal and vertical integration in public and private health systems.Health Care Manag (Frederick). 2007;26:116-27.
51. Weber RS,Lewis CM,Eastman SD,et al.Quality and performance indicators in an academic department of head and neck surgery.Arch Otolaryngol Head Neck Surg. 2010;136:1212-8.
52. McDermott U,Downing JR,Stratton MR.Genomics and the continuum of cancer care.N Engl J Med. 2011;364:340-50.
53. Bojke C,Gravelle H,Wilkin D.Is bigger better for primary care groups and trusts?.BMJ. 2001;322:599-602.
54. Jha AK,Orav EJ,Dobson A,Book RA,Epstein AM.Measuring efficiency: the association of hospital costs and quality of care.Health Aff (Millwood). 2009;28:897-906.
55. Liptak A.On day 3, justices weigh what-ifs of health ruling.NY Times. 2012;:.
56. Gerlinger M,Rowan AJ,Horswell S,et al.Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.N Engl J Med. 2012;366:883-92.
57. Longo DL.Tumor heterogeneity and personalized medicine.N Engl J Med. 2012;366:956-7.